Max Delbrück Center
Register
Register
Register

Alamar Biosciences

Other

alamarbio.comFremont, United States
11 profile visits

About

Alamar Biosciences NULISA technology enables unprecedented attomolar detection of protein biomarkers in a diversity of matrices, enabling early disease detection in neurodegenerative, inflammatory conditions. The NULISA technology is ideal for the translational workflow from preclinics to clinical research, enabling wide detection of biomarkers and focus on the most important ones as endpoints.

Disease Area

CancerInflammation / Autoimmune DiseasesCardiovascular DiseasesInfectious DiseasesMetabolic DiseasesNeurological Diseases

Biomedical Research, Medicine, Human Health

Biomarker DiscoveryEarly DetectionTherapy MonitoringClinical Research, Trials

Technology

Other

Representatives

Regional Business Manager

Alamar Biosciences